Colm J. O'Rourke

Colm J. O'Rourke

Auto-generated profile, based on publicly available information

Colm J. O'Rourke

Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DHDan Dan Høgdall
Dan Dan Høgdall
COColm J. O'Rourke
Colm J. O'Rourke
CDChristian Dehlendorff
Christian Dehlendorff
OLOle F. Larsen
Ole F. Larsen
LJLars Henrik Jensen
Lars Henrik Jensen
JAJesper B Andersen
Jesper B Andersen
Purpose: Biliary tract cancer (BTC) is a heterogeneous group of rare gastrointestinal malignancies with dismal prognosis often associated with inflammation. We assessed the prognostic value of IL6 and YKL-40 compared with CA19-9 before and during palliative chemotherapy. We also investigated in mice whether IL6R inhibition in combination with gemcitabine could prolong chemosensitivity. Experimental Design: A total of 452 Danish participants with advanced (locally advanced and metastatic) BTC were included from six clinical trials (February 2004 to March 2017). Serum CA19-9, IL6, and YKL-40 were measured before and during palliative treatment. Associations between candidate biomarkers and progression-free survival (PFS) and overall survival (OS) were analyzed by univariate and multivariate Cox regression. Effects of inhibiting IL6R and YKL-40 were assessed in vitro, and of IL6R inhibition in vivo. Results: High pretreatment levels of CA19-9, IL6, and YKL-40, and increasing levels during treatment, were associated with short PFS and OS in patients with advanced BTC. IL6 provided independent prognostic information, independent of tumor location and in patients with normal serum CA19-9. ROC analyses showed that IL6 and YKL-40 were predictive of very short OS (OS < 6 months), whereas CA19-9 was best to predict OS > 1.5 years. Treatment with anti-IL6R and gemcitabine significantly diminished tumor growth when compared with gemcitabine monotherapy in an in vivo transplant model of BTC. Conclusions: Serum IL6 and YKL-40 are potential new prognostic biomarkers in BTC. IL6 provides independent prognostic information and may be superior to CA19-9 in certain contexts. Moreover, anti-IL6R should be considered as a new treatment option to sustain gemcitabine response in patients with BTC.

11 February 2025 in Hepatology
Verified
Journal Article
Open access
PRPaula Olaizola Rebe
Paula Olaizola Rebe
IOIrene Olaizola
Irene Olaizola
MAMarta Fernandez de Ara
Marta Fernandez de Ara
ALAinhoa Lapitz
Ainhoa Lapitz
BVBeatriz Val
Beatriz Val
Jesús BañalesJesús Bañales
Jesús Bañales
Background and Aims: Cholangiocarcinoma (CCA) includes a diverse group of biliary malignancies with poor prognosis. Alterations in post-translational modifications contribute to disrupted protein dynamics, cellular disturbances, and disease. This study investigates the role of protein SUMOylation in cholangiocarcinogenesis and its potential as a therapeutic target. Approach and Results: Analysis of CCA tumors from 4 patient cohorts and CCA cell lines, revealed increased expression of the SUMOylation machinery genes SUMO activating enzyme 1 ( SAE1 ) and the SUMO conjugating enzyme UBE2I , regardless of the tumor’s molecular profile, resulting in elevated levels of SUMO1-conjugated proteins. Higher SAE1 and UBE2I levels were both indicative of unfavorable clinical outcomes. Deregulated SUMOylated proteins in CCA, mostly linked to cell proliferation, survival, and homeostasis, were identified through immunoprecipitation and mass spectrometry. Genetic ( UBE2I -knockdown) and pharmacological (ML792 and S-adenosyl-methionine) inhibition of SUMOylation effectively suppressed tumorigenesis in subcutaneous and oncogene-driven CCA models, reducing the presence of cancer-associated fibroblasts and increasing the recruitment of antitumor immune cells. In vitro, targeting SUMOylation induced CCA cell death and reduced cell proliferation, colony formation, and spheroid growth. Importantly, ML792 and S-adenosyl-methionine did not adversely affect normal human cholangiocytes. Moreover, co-culture of wild-type or UBE2I -knockdown CCA cells with cancer-associated fibroblasts revealed that depleting SUMOylation in CCA cells impaired cancer-associated fibroblast cell growth and altered their protein secretome, ultimately disrupting CCA growth through a regulatory feedback loop. Conclusions: Aberrant SUMOylation drives CCA progression by enhancing cell survival, proliferation, and shaping the tumor microenvironment. Targeting SUMOylation shows potential in inhibiting CCA growth, representing a promising therapeutic strategy.

14 April 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DHDan Dan Høgdall
Dan Dan Høgdall
JSJakob V. Schou
Jakob V. Schou
JBJulia Johanna Almer Bromann
Julia Johanna Almer Bromann
JAJesper B Andersen
Jesper B Andersen
COColm J. O’rOurke
Colm J. O’rOurke
Neoadjuvant chemotherapy can down-size or down-stage tumors, minimize post-surgical recurrence risk, or even replace surgery when deployed appropriately for patients with gastrointestinal cancers. However, accomplishing these goals is rate-limited by all-comer treatment protocols, median arm-based comparisons in clinical trials, and the persisting omission of precision approaches for cytotoxic agents. Despite heterogeneity in benefit from standard-of-care regimens, mounting biological data support the presence of actionable sensitivities or potentially targetable dependencies in most tumors. Conceptually, such tumor vulnerabilities could be a game changer. In treatment-resistant malignancies (biliary tract cancer and pancreatic ductal adenocarcinoma), individualized neoadjuvant treatment may increase the curative surgery frequencies that currently occur only in a minority of patients. For more treatment-sensitive gastrointestinal cancers, tailored chemotherapy strategies might reduce the need for high-intensity regimens, minimize post-surgical morbidity, and allow dose de-escalation for selected patients without compromising oncological outcomes. Personalizing chemotherapy strategies remains inferential from comparing outcomes of molecularly distinct patients receiving a single treatment or unselected patients (with comparable baseline characteristics) on different regimens. We discuss the critical importance of harnessing tumor biology to develop and implement predictive signatures for personalized neoadjuvant chemotherapy (alone or in combination with other modalities). This includes exploiting transcriptomics to retrospectively understand the molecular basis of treatment outcomes from patient biopsies, identifying existing agents to replace or supplement current standard of care for those unlikely to respond, and matching novel preclinical treatments to potential responder patients. Deploying mechanistically distinct cytotoxic regimens against gastrointestinal tumors with unique predispositions for DNA damage tolerance is a necessity for boosting neoadjuvant outcomes.

8 May 2025 in Hepatology
Verified
Journal Article
Closed access
COColm J. O’ROurke
Colm J. O’ROurke
JAJesper B Andersen
Jesper B Andersen
An abstract is unavailable. This article is available as a PDF only.

16 November 2026 in bioRxiv
Verified
Preprint
Open access
YLYuewan Luo
Yuewan Luo
ONORESTIS NOUSIAS
ORESTIS NOUSIAS
EZEkaterina Zhuravleva
Ekaterina Zhuravleva
JLJuan Lafuente-Barquero
Juan Lafuente-Barquero
CNChirag Nepal
Chirag Nepal
JAJesper B Andersen
Jesper B Andersen
Summary: More than 50% of cholangiocarcinoma (CCA) patients lack druggable mutations, showing broad non-mutational epigenetic perturbations, whose mechanistic insights and clinical benefit remain largely unexplored. Across multiple CCA patient cohorts, we identified prevalent significant upregulation of lysine demethylase (KDM) gene families, with KDM3B emerging as a critical epigenetic dependency for sustaining tumor fitness. KDM3B loss reduced colony formation, proliferation, and migration across intra- and extrahepatic CCA tumor models. Integrated multi-omics linked KDM3B to ErbB activation and downstream PI3K-AKT oncogenic signaling. Mechanistically, KDM3B is bound to the ERBB3 promoter, removing repressive H3K9me2 marks to transcriptionally activate ERBB3 , augmenting ErbB receptor activity. Spatial and single cell transcriptomics from patient tumors revealed that high KDM3B-ERBB3 coupling reshapes the tumor niche via enhancing the epithelial-mesenchymal transition crosstalk with neighborhood cells to establish a pro-invasive microenvironment. Pharmacologic inhibition in vivo of the KDM3B downstream ERBB-Akt regulatory axis suppressed CCA xenograft tumor growth. These findings establish KDM3B as a non-mutational epigenetic activator of ErbB-driven signaling, reshaping the tumor ecosystem, and defining the KDM3B-ErbB axis as a vulnerability in CCA. Highlights: KDM3B establishes a non-mutational epigenetic dependency that sustains tumor fitness KDM3B activates ErbB signaling via H3K9me2-dependent chromatin regulation of ERBB3 KDM3B-ERBB3 coupling reshapes the tumor ecosystem toward a pro-invasive state Targeting the KDM3B-ERBB-AKT axis suppresses CCA tumor growth